MPM BioImpact-Backed Aktis Seeks to Raise $212 Million in IPO
Wednesday, March 4, 2026 · first reported by Bloomberg
Aktis Pharmaceuticals, backed by MPM BioImpact VC fund, seeks $212 million in IPO. Signals successful exit and portfolio value realization for the fund.
- Firm
- Aktis
- Also named
- MPM BioImpact
- Asset class
- Venture
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
Coverage
1 sourceMore in Deals
From the same day- Burger King UK’s owner agrees proposed deal to buy InterpathThe Independent +2
- Madison Dearborn invests in accounting firm Nichols CauleyPE Hub +3
- Admiral Group completes sale of its U.S. motor business to J.C. Flowersjcfco.com
- Levine Leichtman Capital Partners Announces Sale of Global Loan Agency ServicesPR Newswire